1. OP0034 Efficacy and Safety of Mavrilimumab, A Fully Human Gm–CSFR-Alpha Monoclonal Antibody in Patients with Rheumatoid Arthritis: Primary Results from the Earth Explorer 1 Study. (9th June 2015) Authors: Burmester, G.R.; McInnes, I.B.; Kremer, J.M.; Miranda, P.; Korkosz, M.; Vencovsky, J.; Rubbert-Roth, A.; Mysler, E.; Sleeman, M.A.; Godwood, A.; Albulescu, M.; Close, D.; Weinblatt, M. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0183 Patient Reported Outcomes (PRO) of the Mirai: Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed by Rituximab in DMARD-IR Patients with Rheumatoid Arthritis (MIRAI). (9th June 2015) Authors: Iking-Konert, C.; Burmester, G.-R.; Dörner, T.; Schulze-Koops, H.; Rubbert-Roth, A.; Engel, A.; Gauler, G.; Schwenke, R.; Peters, M.A.; Tony, H.-P. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 721 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0189 Rapid Onset of Clinical Benefit in Patients with RA Treated with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GM–CSFR-ALPHA: Subanalysis of the Phase IIB Earth Explorer 1 Study. (9th June 2015) Authors: McInnes, I.B.; Burmester, G.R.; Kremer, J.M.; Miranda, P.; Korkosz, M.; Vencovsky, J.; Rubbert-Roth, A.; Mysler, E.; Close, D.; Sleeman, M.; Godwood, A.; Albulescu, M.; Weinblatt, M. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 723 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗